Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the Quarter ended December 31, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Venmax Drugs & Pharmaceuticals has submitted a routine compliance certificate to BSE for the quarter ended December 31, 2025, as required under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The company's Registrar and Share Transfer Agent (RTA), CIL Securities Limited, has confirmed that all share dematerialization requests received from Depository Participants during the quarter were processed and confirmed to the Depositories. The original physical share certificates received for dematerialization were mutilated and cancelled after verification, and the Depository names were updated as registered owners in the company's Register of Members within the stipulated timeframe.
No material impact on shareholders or the stock price. This is a standard quarterly procedural filing required by SEBI to ensure proper handling of share dematerialization, with no business or financial implications.